Lung Macrophage Populations and Functions in Chronic Obstructive Pulmonary Disease (COPD)-Susceptible Smokers

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT04722835
Status
Recruiting
Apply to this trial

Conditions

  • Copd
  • Smoking
  • Tobacco Use

Eligibility Criteria

Sex
ALL
Age
40 Years - 75 Years
Healthy Volunteers
Accepted

Interventions

  • Bronchoscopy with Bronchoalveolar Lavage (BAL) — PROCEDURE
    1. Bronchoscopy w/ (BAL): The bronchoscope will be introduced through mouth and directed into the right middle lobe bronchus for bronchial lavage. The BAL will be performed with two 60-mL aliquots (total of 120 ml) of saline in each of medial and lateral segments of Right Middle Lobe (RML) (total 240 ml lavage). 2. Albuterol Administration: The subjects will inhale 2 puffs of respiratory medication albuterol, then repeat the breathing test. 3. Peak Flow Measurement: Subjects will breathe in fully then out forcefully into the handheld device. 4. Pulmonary Function Test w/ Spirometry: will be used for determination of COPD and its severity. The PFT measures breathing capacity and lung function with different types of breathing maneuvers including flow-volume curve, single breath CO diffusing capacity, and total lung capacity. 5. Blood draw 6. Medical Health and Symptom Questionnaires 7. Physical Exam by study doctor to determine suitability and safety for participation.

Study Details

Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous disease that affects only a fraction of those who smoke tobacco. The origin of this variability in susceptibility to develop COPD is unclear, but understanding its underlying biology has important implications for our ability to design suitable preventative and therapeutic strategies for its management. This Department of Defense (DOD) discovery research proposes to develop methodologies and generate preliminary data needed to lay the foundation for a large study that would investigate the underlying biological susceptibility of those who smoke tobacco to develop COPD.

Key Dates

Start date
Mar 1, 2021
Status verified
Jun 2026
Primary completion
Dec 31, 2030
Completion
Dec 31, 2030

Study Design

Enrollment
40 participants (estimated)

Arms

  • Arm: Normal RV/TLC Group:
    Plethysmographic RV/TLC equal or less than lower limit of normal.
  • Arm: Abnormal RV/TLC Group:
    Plethysmographic RV/TLC higher than lower limit of normal.

Primary Outcome Measure

Prevalence of macrophage sub-populations in airway lumen. [ Time Frame: 4 weeks ]

Central Contacts

Locations (3)

FacilityCityStateZIP
San Francisco VA Medical CenterSan FranciscoCalifornia94121
University of California, San FranciscoSan FranciscoCalifornia94122
Zuckerberg San Francisco General Hospital and Trauma CenterSan FranciscoCalifornia94110

Find similar trials in San Francisco, CA

By condition
COPD
By specialty
PulmonologyLung disease
By research site
San Francisco VA Medical Center· San Francisco, CAUniversity of California, San Francisco· San Francisco, CAZuckerberg San Francisco General Hospital and Trauma Center· San Francisco, CA

Related Studies